SCHEMBL5510401

SCHEMBL5510401

CNc1cc2c(cc1Cl)C(=O)N(c1ccc(N)cc1)CO2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.35
RAD51 Q06609 1/20 0.32
LMNA P02545 2/20 0.32
MAPT P10636 2/20 0.32
ALOX12 P18054 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ALDH1A1 P00352 2/20 0.31
NPC1 O15118 1/20 0.31
TSHR P16473 1/20 0.31
CASP1 P29466 1/20 0.31
RAB9A P51151 1/20 0.31
CASP7 P55210 1/20 0.31
HSD17B10 Q99714 1/20 0.31
WEE1 P30291 1/20 0.31
GRM2 Q14416 1/20 0.30
CYP3A4 P08684 1/20 0.30
NFKB1 P19838 1/20 0.30
PMP22 Q01453 1/20 0.30
CHEK1 O14757 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5511162 0.87 SCN2A (0.36) LMNAMAPTSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL5511797 0.86 MAPK14 (0.34) ALDH1A1NPC1TSHRCASP1RAB9A
SCHEMBL5510340 0.75 P2RY12 (0.50) LMNAMAPTSMN1; SMN2ALDH1A1CYP3A4
SCHEMBL12768201 0.74 ALDH1A1 (0.32) LMNASMN1; SMN2ALDH1A1
SCHEMBL14544536 0.73 P2RY12 (0.34) SMN1; SMN2
SCHEMBL5509910 0.73 MAPT (0.36) LMNAMAPTSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL14522043 0.73 F10 (0.33) GRM2
SCHEMBL5508565 0.72 ALOX5AP (0.34) LRRK2WEE1
SCHEMBL14522045 0.69 NR4A1 (0.37) LMNAMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL5513494 0.68 POLB (0.41) LMNAMAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7205296-B2 Substituted 2H-1,3-benzoxazin-4(3H)-ones PORTOLA PHARMACEUTICALS, INC. (US) 2007-04-17 US disclosed
US-7205296-B2 Substituted 2H-1,3-benzoxazin-4(3H)-ones PORTOLA PHARMACEUTICALS, INC. (US) 2007-04-17 US disclosed
US-7205296-B2 Substituted 2H-1,3-benzoxazin-4(3H)-ones PORTOLA PHARMACEUTICALS, INC. (US) 2007-04-17 US disclosed
US-20060069093-A1 Substituted 2H-1,3-benzoxazin-4(3H)-ones PORTOLA PHARMACEUTICALS, INC. (US) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069093-A1 Substituted 2H-1,3-benzoxazin-4(3H)-ones TBXAS1, TBXA2R, SERPINC1 LRRK2 4411/4885RAD51 687/4885LMNA 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.